Final outcome of IBS' rights issue IBS' new share issue with preferential rights for the Company's existing shareholders has been completed. Deccan Value Advisors, having issued a subscription guarantee, subscribed for its pro rata share of the rights issue and an additional 75,000 class A shares and an additional 11,087,943 class B shares. Accordingly, the rights issue was subscribed for in its entirety. According to a July 4 Deccan Value Advisors press release, Deccan Value Advisors owns 20.0 percent of the shares and 38.7 percent of the votes in IBS. As a consequence of the rights issue, the number of shares in IBS increases by 1,575,000 class A shares and 40,229,015 class B shares. Following the issue, 4,725,000 class A shares and 120,687,045 class B shares will be outstanding. Trading in the new class B shares on OMX Nordic Exchange Stockholm is scheduled to commence on July 17, 2008. The rights issue will provide the company with approximately SEK 397 million before transaction costs. Additional class B shares will be issued shortly as consideration for Deccan Value Advisors subscription guarantee. The exact number of shares issued will be stated in a separate press release as soon as the formal resolution to issue the shares has been adopted. IBS AB Board of Directors For further information, please contact: Investor Relations Director Oskar Ahlberg Tel: +46 (0)70 244 24 75, oskar.ahlberg@ibs.net IBS in brief With over 30 years of supply chain expertise, IBS is a leading provider of complete ERP solutions. IBS focuses on mid-sized and large distribution companies, as well as sales and manufacturing subsidiaries of international groups, mainly within industries such as automotive, electrical, food, industrial supplies, paper, pharmaceutical, publishing and wholesale distribution. More than 5,000 customers across some 40 countries use IBS software to gain fast and measurable returns on IT investments. IBS B share is listed on OMX Nordic Exchange Stockholm. For more information, please visit www.ibs.net
Final outcome of IBS' rights issue
| Source: IBS AB